Genotype-based clinical trials in cardiovascular disease.

ABSTRACT: Consensus practice guidelines and the implementation of clinical therapeutic advances are usually based on the results of large, randomized clinical trials (RCTs). However, RCTs generally inform us on an average treatment effect for a presumably homogeneous population, but therapeutic interventions rarely benefit the entire population targeted. Indeed, multiple RCTs have demonstrated that interindividual variability exists both in drug response and in the development of adverse effects. The field of pharmacogenomics promises to deliver the right drug to the right patient. Substantial progress has been made in this field, with advances in technology, statistical and computational methods, and the use of cell and animal model systems. However, clinical implementation of pharmacogenetic princ

SUBMITTER: Pereira NL 

PROVIDER: S-EPMC4687401 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature